Research programme: Alzheimer's disease therapy - Satori Pharmaceuticals
Alternative Names: Alzheimer's disease therapy research programme - Satori Pharmaceuticals; SPI 1865; SPI-014Latest Information Update: 04 Nov 2017
Price :
$50 *
At a glance
- Originator Satori Pharmaceuticals
- Class
- Mechanism of Action Amyloid precursor protein secretase modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Alzheimer's-disease in USA
- 11 Jul 2012 Preclinical development is ongoing in USA
- 20 Jul 2011 This programme is in active development